Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axogen, Inc. filings document a Nasdaq-listed operating company focused on peripheral nerve repair technologies and related surgical products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor presentations, FDA-related disclosures for Avance® (acellular nerve allograft-arwx), and material agreements tied to common stock financing and shelf registration activity.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and pay-versus-performance disclosures. The filing record also identifies Axogen’s common stock structure and corporate governance framework, while event reports record officer compensation arrangements, regulatory language for Avance, and other formal updates to the company’s public disclosure record.
Erick DeVinney, listed as Chief Innovation Officer and a director of Axogen, Inc. (AXGN), reported equity activity related to performance stock units. On 09/13/2025 2,500 shares of common stock were issued upon attainment of specified performance criteria, bringing his beneficial ownership to 221,786 shares. To satisfy tax withholding triggered by the vesting, the issuer's plan required a "sell-to-cover" transaction: on 09/16/2025 Mr. DeVinney sold 1,137 shares at $16.29 per share, reducing his beneficial ownership to 220,649 shares. The Form 4 indicates the sale was required by the company election under its equity incentive plans and was not a discretionary trade by the reporting person.
Axogen, Inc. reported that the U.S. Food and Drug Administration has classified its recent facility and manufacturing information submission as a Major Amendment to the Biologics License Application for Avance® Nerve Graft. As a result, the FDA extended the Prescription Drug User Fee Act goal date to December 5, 2025, a three-month delay consistent with FDA guidelines for major amendments. The FDA also now expects to provide feedback on product labeling in November 2025, giving a clearer timeframe for the next regulatory milestone.
Axogen, Inc. (AXGN) filed an 8-K on August 5, 2025.
The filing furnishes a press release announcing second quarter 2025 financial results (Exhibit 99.1) and a second quarter 2025 financial results presentation posted to the company website and furnished as Exhibit 99.2. The company explicitly states these items are furnished, not filed, and therefore not subject to Section 18 liability or incorporated by reference unless expressly stated in a future filing.
The report is signed by Marc Began, Executive Vice President, General Counsel and Chief Compliance Officer.
Axogen, Inc. (AXGN) – Form 4 insider filing
Director Amy McBride Wendell received an annual equity grant of 14,150 restricted stock units (RSUs) on 06/19/2025. The award is valued at $150,000 and represents the company’s standard director compensation. Each RSU converts to one common share upon vesting, which occurs in a single tranche on 06/19/2026, the one-year anniversary of the grant date. Following the transaction, Wendell’s directly held derivative position totals 14,150 RSUs; no open-market purchases or sales of common stock were reported. The filing does not indicate the adoption of a Rule 10b5-1 trading plan, and no other securities were acquired or disposed of.
Because the award is part of routine board compensation rather than an opportunistic purchase, the filing is unlikely to have a material impact on AXGN’s share price but does underscore continued alignment between the director and shareholder interests through equity-based pay.
Axogen, Inc. (AXGN) filed a Form 4 disclosing that Director Kathy Johnson Weiler received an annual equity grant of 14,150 restricted stock units (RSUs) on 06/19/2025. Each RSU converts into one share of common stock upon vesting, giving Weiler contingent rights to the same number of shares.
The grant is valued at approximately $150,000 based on Axogen’s share price at the grant date and vests in full on 06/19/2026, the one-year anniversary of the award. Following the transaction, the director beneficially owns 14,150 AXGN shares, all held directly. No shares were sold or otherwise disposed of.
The filing reflects routine board compensation, introduces no immediate cash outflow for the company, and does not materially change Axogen’s share count or insider ownership profile.
Form 4 snapshot: Axogen, Inc. (AXGN) disclosed that Director William P. Burke received 14,150 restricted stock units (RSUs) on 06/19/2025 as his annual board equity retainer, valued at approximately $150,000 on the grant date. The transaction is coded “A” (acquisition), confirming that no open-market trade occurred.
Each RSU converts to one share of common stock upon vesting, which is scheduled for 06/19/2026, the first anniversary of the grant. Until then the award remains a contingent right rather than outstanding shares.
Following the award Mr. Burke’s derivative holdings increased by 14,150 units, all held directly. The filing reports no dispositions, option exercises or sales, and does not affect the company’s share count or cash position. The grant aligns director compensation with long-term shareholder value and is routine under Axogen’s board compensation program.